Pharma Journalist -

Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline as the company is adding an innovative preclinical program with the acquisition of Nerio…
Read More...

Novartis announced that Scemblix (asciminib) has been granted Priority Review status by the US Food and Drug Administration (FDA) for treatment of newly diagnosed adult patients with…
Read More...

Sandoz, the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva®* (ustekinumab) across Europe, starting today. Pyzchiva®, developed and registered by…
Read More...

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, announced that its active-immunotherapy candidate, ACI-35.030 (now…
Read More...

Ipsen and Day One Biopharmaceuticals (Day One), announced a new global partnership outside the U.S. for tovorafenib, an oral, once-weekly, type II RAF inhibitor for pediatric low grade…
Read More...

Astellas Pharma Inc. and Graduate School of Medicine / Faculty of Medicine, Osaka University announced that Astellas Institute for Regenerative Medicine (a wholly owned subsidiary of…
Read More...

The Phase III ARANOTE trial, investigating NUBEQA (darolutamide) plus androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC),…
Read More...

Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and development, announced the completion of $35 Million Series A+ financing. This round…
Read More...

CatalYm announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s…
Read More...

Merck, a leading science and technology company, announced the start of commercial production of its first GMP (Good Manufacturing Practices) compliant manufacturing line for cell…
Read More...